PRINCETON, N.J.–Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). In R/R CLL or SLL, Breyanzi is delivered through a treatment process which culminates in a one-time infusion* with a single dose containing 90 to 110 x 106 CAR-positive viable T cells.Continue reading→

Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed

20,000-participant BLUE-C study included 98 colorectal cancers and reflects racial and ethnic diversity of U.S.

Company will host conference call and webcast at 8:00 a.m. ET on March 14 to discuss study resultsContinue reading→

WASHINGTON, D.C. – Today, AdvaMed, the Medtech Association, announced Board Chairman Peter Arduini’s priorities to guide the vision of the medtech industry over the course of his two-year term. The priorities, which are established by each new Board chair, come as AdvaMed, the leading trade association, renews its advocacy efforts in Washington and globally to address key issues impacting medtech companies and the providers and patients they serve.Continue reading→

AZBio Team Members traveled to our nation’s capitol to meet with our Arizona Congressional Delegation and to share how current policies and proposed laws can help or hinder medtech innovation. Continue reading→

• Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response
• Nature Medicine paper highlights delivery of CAR T cell therapy directly to the brain, a technique City of Hope developed
• This is the largest reported trial to date of CAR T therapy for solid tumors

Continue reading→

The Phoenix Bioscience Core is excited to welcome the Arizona Bioindustry Association, Inc. (AZBio) to the PBC. Its new office in Connect Labs by Wexford Science + Technology expands on AZBio’s close relationship with the PBC and its community members. Continue reading→

• Reglagene’s RGN6024 is on track to give new hope to provide orally administered therapy for brain cancer patients whose survival has historically been very low.
• Will speed development of RGN6024 therapy into the clinic

Continue reading→

The Riskguard test detects genetic changes that can increase risk for 10 common cancers, using a simple blood or saliva sample
The test is covered by Medicare and many commercial insurance plans for eligible patientsContinue reading→